1. Rickinson AB, Kieff E (2001). Epstein-Barr virus. In: Knipe DM, Howley PM (eds). Fields virology, vol. 2, 4th edn. Lippincott Williams and Wilkins: Philadelphia, PA, pp 2575-2628.

2. Pope JH, Horne MK, Scott W (1968). Transformation of foetal human keukocytes in vitro by filtrates of a human leukaemic cell line containing herpes-like virus. Int J Cancer 3(6): 857-866.

3. Nilsson K, Ponten J (1975). Classification and biological nature of established human hemat-opoietic cell lines. Int J Cancer 15(2): 321-341.

4. Klein G (1994). Epstein-Barr virus strategy in normal and neoplastic B cells. Cell 77(6): 791-793.

5. Rowe M, Lear AL, Croom-Carter D, Davies AH, Rickinson AB (1992). Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J Virol 66(1): 122-131.

6. Thorley-Lawson DA (2001). Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 1(1):75-82.

7. Hammerschmidt W, Sugden B (1989). Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature 340(6232): 393-397.

8. Kaye KM, Izumi KM, Kieff E (1993). Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci USA 90(19): 9150-9154.

9. Young L, Alfieii C, Hennessy K, Evans H, O'Hara C, Anderson KC, Ritz J, Shapiro RS, Rickinson A, Kieff E, Cohen JI (1989). Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBVlymphoproliferative disease. N Engl J Med 321(16): 1080-1085.

10. Epstein MA, Achong BG, Barr YM (1964). Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 15: 702-703.

11. Rowe M, Rowe DT, Gregory CD, Young LS, Farrell PJ, Rupani H, Rickinson AB (1987). Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J 6(9): 2743-2751.

12. Chen F, Zou JZ, di Renzo L, Winberg G, Hu LF, Klein E, Klein G, Ernberg I (1995). A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1. J Virol 69(6): 3752-3758.

13. Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA (1998). EBV persistence in memory B cells in vivo. Immunity 9(3): 395-404.

14. Deacon EM, Pallesen G, Niedobitek G, Crocker J, Brooks L, Rickinson AB, Young LS (1993). Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med 177(2): 339-349.

15. Chiang AK, Tao Q, Srivastava G, Ho FC (1996). Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease. Int J Cancer 68(3): 285-290.

16. Fahraeus R, Fu HL, Ernberg I, Finke J, Rowe M, Klein G, Falk K, Nilsson E, Yadav M, Busson P, Tursz T, Kallin B (1988). Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer 42(3): 329-338.

17. Klein E, Kis LL, Klein G (2007). Epstein-Barr virus infektion in humans: from harmless to life endangering virus-lymphocyte interactions. Oncogene, In Press.

18. Doyle MG, Catovsky D, Crawford DH (1993). Infection of leukaemic B lymphocytes by Epstein Barr virus. Leukemia 7(11): 1858-1864.

19. Teramoto N, Gogolak P, Nagy N, Maeda A, Kvarnung K, Bjorkholm M, Klein E (2000). Epstein-Barr virus-infected B-chronic lymphocyte leukemia cells express the virally encoded nuclear proteins but they do not enter the cell cycle. J Hum Virol 3(3): 125-136.

20. Kis LL, Takahara M, Nagy N, Klein G, Klein E (2006a). IL-10 can induce the expression of EBV-encoded latent membrane protein-1 (LMP-1) in the absence of EBNA-2 in B lymphocytes and in Burkitt lymphoma- and NK lymphoma-derived cell lines. Blood 107(7): 2928-2935.

21. Kis LL, Takahara M, Nagy N, Klein G, Klein E (2006b). Cytokine mediated induction of the major Epstein-Barr virus (EBV)-encoded transforming protein, LMP-1. Immunol Lett 104(1-2): 83-88.

22. Babcock GJ, Hochberg D, Thorley-Lawson DA (2000). The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 13(3): 497-506.

23. Hochberg D, Middeldorp JM, Catalina M, Sullivan JL, Luzuriaga K, Thorley-Lawson DA (2004). Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proc Natl Acad Sci USA 101(1): 239-244.

24. Contreras-Brodin BA, Anvret M, Imreh S, Altiok E, Klein G, Masucci MG (1991). B cell phenotype-dependent expression of the Epstein-Barr virus nuclear antigens EBNA-2 to EBNA-6: studies with somatic cell hybrids. J Gen Virol 72(Pt 12): 3025-3033.

25. Maeda A, Bandobashi K, Nagy N, Teramoto N, Gogolak P, Pokrovskaja K, Szekely L, Bjorkholm M, Klein G, Klein E (2001). Epstein-barr virus can infect B-chronic lymphocytic leukemia cells but it does not orchestrate the cell cycle regulatory proteins. J Hum Virol 4(5): 227-237.

26. Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS (1991). Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 337(8737): 320-322.

27. Hjalgrim H, Askling J, Rostgaard K, Hamilton-Dutoit S, Frisch M, Zhang JS, Madsen M, Rosdahl N, Konradsen HB, Storm HH, Melbye M (2003). Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N Engl J Med 349(14): 1324-1332.

28. Kanzler H, Kuppers R, Hansmann ML, Rajewsky K (1996). Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 184(4): 1495-1505.

29. Kuppers R (2002). Molecular biology of Hodgkin's lymphoma. Adv Cancer Res 84: 277-312.

30. Kuppers R, Rajewsky K, Zhao M, Simons G, Laumann R, Fischer R, Hansmann ML (1994). Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci USA 91(23): 10962-10966.

31. Hertel CB, Zhou XG, Hamilton-Dutoit SJ, Junker S (2002). Loss of B cell identity correlates with loss of B cell-specific transcription factors in Hodgkin/Reed-Sternberg cells of classical Hodgkin lymphoma. Oncogene 21(32): 4908-4920.

32. Schwering I, Brauninger A, Klein U, Jungnickel B, Tinguely M, Diehl V, Hansmann ML, Dalla-Favera R, Rajewsky K, Kuppers R (2003). Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 101(4): 1505-1512.

33. Contreras-Brodin B, Karlsson A, Nilsson T, Rymo L, Klein G (1996). B cell-specific activation of the Epstein-Barr virus-encoded C promoter compared with the wide-range activation of the Wpromoter. J Gen Virol 77(Pt 6): 1159-1162.

34. Tierney R, Kirby H, Nagra J, Rickinson A, Bell A (2000). The Epstein-Barr virus promoter initiating B-cell transformation is activated by RFX proteins and the B-cell-specific activator protein BSAP/Pax5. J Virol 74(22): 10458-10467.

35. Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W, Royer HD, Grinstein E, Greiner A, Scheidereit C, Dorken B (1997). Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 100(12): 2961-2969.

36. Cabannes E, Khan G, Aillet F, Jarrett RF, Hay RT (1999). Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha. Oncogene 18(20): 3063-3070.

37. Martin-Subero JI, Gesk S, Harder L, Sonoki T, Tucker PW, Schlegelberger B, Grote W, Novo FJ, Calasanz MJ, Hansmann ML, Dyer MJ, Siebert R (2002). Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood 99(4): 1474-1477.

38. Carbone A, Gloghini A, Gruss HJ, Pinto A (1995). CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease. Am J Pathol 147(4): 912-922.

39. Horie R, Watanabe T, Morishita Y, Ito K, Ishida T, Kanegae Y, Saito I, Higashihara M, Mori S, Kadin ME, Watanabe T (2002). Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells. Oncogene 21(16): 2493-2503.

40. van den Berg A, Visser L, Poppema S (1999). High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanationfor the characteristic T-cell infiltratein Hodgkin's lymphoma. Am J Pathol 154(6): 1685-1691.

41. Nakayama T, Hieshima K, Nagakubo D, Sato E, Nakayama M, Kawa K, Yoshie O (2004). Selective induction of Th2-attracting chemokines CCL17 and CCL22 in human B cells by latent membrane protein 1 of Epstein-Barr virus. J Virol 78(4): 1665-1674.

42. Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN, Vickers MA

(2004). Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 103(5): 1755-1762.

43. Ishida T, Ishii T, Inagaki A, Yano H, Komatsu H, Iida S, Inagaki H, Ueda R (2006). Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res 66(11): 5716-5722.

44. Dukers DF, Meij P, Vervoort MB, Vos W, Scheper RJ, Meijer CJ, Bloemena E, Middeldorp JM (2000). Direct immunosuppressive effects of EBV-encoded latent membrane protein 1. J Immunol 165(2): 663-670.

45. Staratschek-Jox A, Wolf J, Diehl V (2000). Hodgkin's disease. In: Masters JRW, Palsson BO (eds). Human cell culture, vol. 3. Kluwer: Dordrecht, pp 339-353.

46. Vockerodt M, Belge G, Kube D, Irsch J, Siebert R, Tesch H, Diehl V, Wolf J, Bullerdiek J, Staratschek-Jox A (2002). An unbalanced translocation involving chromosome 14 is the probable cause for loss of potentially functional rearranged immunoglobulin heavy chain genes in the Epstein-Barr virus-positive Hodgkin's lymphoma-derived cell line L591. Br J Haematol 119(3): 640-646.

47. Kis LL, Nishikawa J, Takahara M, Nagy N, Matskova L, Takada K, Elmberger PG, Ohlsson A, Klein G, Klein E (2005). In vitro EBV-infected subline of KMH2, derived from Hodgkin lymphoma, expresses only EBNA-1, while CD40 ligand and IL-4 induce LMP-1 but not EBNA-2. Int J Cancer 113(6): 937-945.

48. Baumforth KR, Flavell JR, Reynolds GM, Davies G, Pettit TR, Wei W, Morgan S, Stankovic T, Kishi Y, Arai H, Nowakova M, Pratt G, Aoki J, Wakelam MJ, Young LS, Murray PG

(2005). Induction of autotaxin by the Epstein-Barr virus promotes the growth and survival of Hodgkin lymphoma cells. Blood 106(6): 2138-2146.

49. Atayar C, Poppema S, Visser L, van den Berg A (2006). Cytokine gene expression profile distinguishes CD4+/CD57+ T cells of the nodular lymphocyte predominance type of Hodgkin's lymphoma from their tonsillar counterparts. J Pathol 208(3): 423-430.

50. Anastasiadou E, Boccellato F, Cirone M, Kis LL, Klein E, Frati L, Faggioni A, Trivedi P (2005). Epigenetic mechanisms do not control viral latency III in primary effusion lymphoma cells infected with a recombinant Epstein-Barr virus. Leukemia 19: 1854-1856.

51. Arguello M, Sgarbanti M, Hernandez E, Mamane Y, Sharma S, Servant M, Lin R, Hiscott J (2003). Disruption of the B-cell specific transcriptional program in HHV-8 associated primary effusion lymphoma cell lines. Oncogene 22: 964-973.

52. Babcock GJ, Thorley-Lawson DA (2000). Tonsillar memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors. Proc Natl Acad Sci USA 97: 12250-12255.

53. Frisan T, Sjoberg J, Dolcetti R, Boiocchi M, De Re V, Carbone A, Brautbar C, Battat S, Biberfeld P, Eckman M, Öst A, Christensson B, Sundström C, Björkholm M, Pisa P, Masucci MG (1995). Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood 86(4): 1493-1501.

54. Harabuchi Y, Yamanaka N, Kataura A, Imai S, Kinoshita T, Mizuno F, Osato T (1990). Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet 335(8682): 128-130.

55. Tsuge I, Morishima T, Morita M, Kimura H, Kuzushima K, Matsuoka H (1999). Characterization of Epstein-Barr virus (EBV)-infected natural killer (NK) cell proliferation in patients with severe mosquito allergy; establishment of an IL-2-dependent NK-like cell line. Clin Exp Immunol 115(3): 385-392.

56. Zhang Y, Nagata H, Ikeuchi T, Mukai H, Oyoshi MK, Demachi A, Morio T, Wakiguchi H, Kimura N, Shimizu N, Yamamoto K (2003). Common cytological and cytogenetic features of Epstein-Barr virus (EBV)-positive natural killer (NK) cells and cell lines derived from patients with nasal T/NK-cell lymphomas, chronic active EBV infection and hydroa vacciniforme-like eruptions. Br J Haematol 121(5): 805-814.

57. Takahara M, Kis LL, Nagy N, Liu A, Harabuchi Y, Klein G, Klein E (2006). Concomitant increase of LMP1 and CD25 (IL-2-receptor alpha) expression induced by IL-10 in the EBV-positive NK lines SNK6 and KAI3. Int J Cancer 119(12): 2775-2783.

Was this article helpful?

0 0
10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment